26 July 2017

Mercure Manchester Piccadilly, Portland Street, Manchester, M1 4PH

Final agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Appraisal  of cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer [ID56]
               4.1 Declarations of interest  Part 1 only (open session)
               4.2 Introduction by the Chair, professor Gary McVeigh - Part 1 only (open session)
               4.3 Presentation by the lead team - Part 1 AND part 2 (open and closed session)
               4.4 Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  5. Appraisal of tofacitinib for treating moderate to severe active rheumatoid arthritis after the failure of disease-modifying anti-rheumatic drugs [ID526]
    • 5.1. Declarations of interest – Part 1 only (open session)
    • 5.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
    • 5.3. Presentation by the lead team – Part 1 AND part 2 (open and closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85) [ID456] and Immunosuppressive therapy for kidney transplantation in children and adolescents (review of technology appraisal guidance 99) [ID346]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
    • 6.3. Presentation by the Chair, Professor Gary McVeigh – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of ixazomib citrate for treating relapsed or refractory multiple myeloma [ID807]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
    • 7.3. Presentation by the Chair, Professor Gary McVeigh – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Wednesday 30 August 2017 at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Wednesday 12 July 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Jon Littler.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 28 June 2017 to 12 July 2017
Registration is closed.